Response to Treatment with Yttrium 90-DOTA-Lanreotide of a Patient with Metastatic Gastrinoma

1,4,7,10-tetraazacyclododecane-N,N',N",N'''-tetraacetic acid (DOTA)-lanreotide is a universal somatostatin (SST) receptor subtype ligand that binds to a large variety of human tumors. We report the case of a patient with metastatic gastrinoma who was treated with 90Y-DOTA-la...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of nuclear medicine (1978) Vol. 39; no. 12; pp. 2090 - 2094
Main Authors:	Leimer, Maria, Kurtaran, Amir, Smith-Jones, Peter, Raderer, Markus, Havlik, Erst, Angelberger, Peter, Vorbeck, Friedrich, Niederle, Bruno, Herold, Christian, Virgolini, Irene
Format:	Journal Article
Language:	English
Published:	Reston, VA Soc Nuclear Med 01-12-1998 Society of Nuclear Medicine
Subjects:	Biological and medical sciences Digestion. Liver. Biliary tract. Spleen. Pancreas Gastrinoma - diagnostic imaging Gastrinoma - pathology Gastrinoma - radiotherapy Gastrinoma - secondary Heterocyclic Compounds - pharmacokinetics Heterocyclic Compounds - therapeutic use Humans Investigative techniques, diagnostic techniques (general aspects) Liver Neoplasms - diagnostic imaging Liver Neoplasms - radiotherapy Liver Neoplasms - secondary Lymph Node Excision Male Medical sciences Metabolic Clearance Rate Middle Aged Pancreatic Neoplasms - pathology Pancreatic Neoplasms - radiotherapy Pancreatic Neoplasms - surgery Peptides, Cyclic - pharmacokinetics Peptides, Cyclic - therapeutic use Radionuclide investigations Radiopharmaceuticals - pharmacokinetics Radiopharmaceuticals - therapeutic use Receptors, Somatostatin - agonists Recurrence Tomography, Emission-Computed, Single-Photon Tomography, X-Ray Computed Endocrinopathy Radionuclide study Human Treatment efficiency Male Scintigraphy Radiotherapy Gastrinoma Secretory tumor Case study Chemotherapy Surveillance Lanreotide Digestive diseases Medical imagery Adult Dosimetry Somatostatin Yttrium
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	1,4,7,10-tetraazacyclododecane-N,N',N",N'''-tetraacetic acid (DOTA)-lanreotide is a universal somatostatin (SST) receptor subtype ligand that binds to a large variety of human tumors. We report the case of a patient with metastatic gastrinoma who was treated with 90Y-DOTA-lanreotide. Before treatment, dosimetry with 111In-DOTA-lanreotide (150 MBq, 10 nmol) indicated a dose of 5.8 mGy/MBq for the recurrent abdominal gastrinoma, and a mean dose of approximately 1.0 mGy/MBq for liver metastases (i.e., 56 and approximately 10 mGy/MBq for 90Y-DOTA-lanreotide, respectively). After four infusions of 90Y-DOTA-lanreotide (each 1 GBq, approximately 30 nmol) over a 6-mo period, the 111In-DOTA-lanreotide scintigraphy of the liver had returned to a nearly normal condition and a remarkably decreased uptake by the recurrent gastrinoma was calculated (approximately 5 mGy/MBq for 90Y-DOTA-lanreotide). The imaging results were well-correlated with a 25% regression of the liver metastases as indicated by CT. Blood, urine and whole-body clearances of 111In-DOTA-lanreotide and 90Y-DOTA-lanreotide were very similar. The DOTA-lanreotide promises to be useful for functional tumor diagnosis (111In-DOTA-lanreotide) and receptor-mediated tumor radiotherapy (90Y-DOTA-lanreotide).
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	0161-5505 1535-5667